Structural and Functional Myocardial Responses to Chronic Treatment with the Ca2+ Blocker Verapamil (Calan-SR) in Hypertensive Patients

SUMMARYWe wished to determine whether prolonged therapy with the Ca channel blocker verapamil has beneficial structural and functional cardiac effects. Nine hypertensive outpatients [systolic blood pressure (SBP) 164 ± 4 and diastolic BP (DBF) 103 ± 4 mm Hgmen and women, blacks and whites, mean age...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cardiovascular pharmacology 1993-10, Vol.22 (4), p.637-643
Hauptverfasser: Howley, John W, Formolo, John M, Penney, David G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 643
container_issue 4
container_start_page 637
container_title Journal of cardiovascular pharmacology
container_volume 22
creator Howley, John W
Formolo, John M
Penney, David G
description SUMMARYWe wished to determine whether prolonged therapy with the Ca channel blocker verapamil has beneficial structural and functional cardiac effects. Nine hypertensive outpatients [systolic blood pressure (SBP) 164 ± 4 and diastolic BP (DBF) 103 ± 4 mm Hgmen and women, blacks and whites, mean age 48.6 years] received 240–480 mg slow-release verapamil (Calan-SR) a day. BP, left ventricle (LV) wall thickness and mass, and mitral flow characteristics on echocardiography, and plasma catechols and renin were determined at 0, 5, 10, and 15 months. Patients were compared with 10 normotensive controls, of similar group composition (SBP 130 ± 3 and DBP 82 ± 1 mm Hg; age 47.2 years). In the hypertensive patients, SBP and DBP decreased significantly (p < 0.05), by 14 and 12 mm Hg, respectively, but remained well above that of controls and > 140/90 mm Hg. Diastolic LV septal thickness decreased from 15.3 ± 0.6 to 14.5 ± 1.1 mm (not significant), while diastolic LV posterior wall thickness (PWTd) decreased significantly (p < 0.05) from 15.7 ± 0.6 to 14.1 ± 0.7 mm after 8 months, but not to the value of the controls. LV diastolic and systolic and left atrial dimensions remained constant. Normalized LV mass, initially 60% greater than the controls, decreased slightly (11%) but nonsignificantly and remained above that of controls. Neither LV mass nor LV posterior wall thinning was correlated with reduction in BP. Patient peak systolic wall stress was initially significantly lower than that of controls. The Doppler-derived E/PWTd ratio, which was initially significantly decreased relative to that of controls, increased, becoming nonsignificantly different from that of controls. Normalization of the E/PWTd ratio suggests improved LV diastolic performance, particularly with regard to early diastolic filling. Norepinephrine (NE) decreased significantly (66%, p > 0.05), suggesting that verapamil decreased overall sympathetic ad-renergic stimulation. There was no change in epinephrine or plasma renin. Thus, > 1-year verapamil therapy in middle-aged hypertensive patients produces improvement in LV diastolic function and slight reduction in LV wall thickness.
doi_str_mv 10.1097/00005344-199310000-00019
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76134659</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76134659</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4349-14c07dab825a6b9c360662556b220e449d8335a4f350c2dc7563c97751aa1bf53</originalsourceid><addsrcrecordid>eNp1kt9uFCEUxonR1LX6CCZcGGNjRmH4MzuXOmmtSY2mrd6SMwyTxTIwBcbNPoGvLXXXvZPkBE7O7zuc8IEQpuQdJW3znpQlGOcVbVtGH7KqBG0foRUVjFWc1OwxWhEqSVVzLp-iZyn9LAQXjTxBJ40ocrleod83OS46LxEcBj_gi8XrbIMv6Zdd0BAHW47XJs3BJ5NwDrjbxOCtxrfRQJ6Mz3hr8wbnjcEd1G_xRxf0nYn4h4kww2QdftOBA1_dXJ9h6_HlbjYxG5_sL4O_QbalRXqOnozgknlx2E_R94vz2-6yuvr66XP34arSnPG2olyTZoB-XQuQfauZJFLWQsi-ronhvB3WjAngIxNE14NuhGS6bRpBAWg_CnaKXu_7zjHcLyZlNdmkjSvzmbAk1UjKuBRtAdd7UMeQUjSjmqOdIO4UJerBA_XPA3X0QP31oEhfHu5Y-skMR-Hh0Uv91aEOSYMbI3ht0xHjLeVM1gXje2wbXDYx3blla6LaGHB5o_73A9gfV7ad6Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76134659</pqid></control><display><type>article</type><title>Structural and Functional Myocardial Responses to Chronic Treatment with the Ca2+ Blocker Verapamil (Calan-SR) in Hypertensive Patients</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><creator>Howley, John W ; Formolo, John M ; Penney, David G</creator><creatorcontrib>Howley, John W ; Formolo, John M ; Penney, David G</creatorcontrib><description>SUMMARYWe wished to determine whether prolonged therapy with the Ca channel blocker verapamil has beneficial structural and functional cardiac effects. Nine hypertensive outpatients [systolic blood pressure (SBP) 164 ± 4 and diastolic BP (DBF) 103 ± 4 mm Hgmen and women, blacks and whites, mean age 48.6 years] received 240–480 mg slow-release verapamil (Calan-SR) a day. BP, left ventricle (LV) wall thickness and mass, and mitral flow characteristics on echocardiography, and plasma catechols and renin were determined at 0, 5, 10, and 15 months. Patients were compared with 10 normotensive controls, of similar group composition (SBP 130 ± 3 and DBP 82 ± 1 mm Hg; age 47.2 years). In the hypertensive patients, SBP and DBP decreased significantly (p &lt; 0.05), by 14 and 12 mm Hg, respectively, but remained well above that of controls and &gt; 140/90 mm Hg. Diastolic LV septal thickness decreased from 15.3 ± 0.6 to 14.5 ± 1.1 mm (not significant), while diastolic LV posterior wall thickness (PWTd) decreased significantly (p &lt; 0.05) from 15.7 ± 0.6 to 14.1 ± 0.7 mm after 8 months, but not to the value of the controls. LV diastolic and systolic and left atrial dimensions remained constant. Normalized LV mass, initially 60% greater than the controls, decreased slightly (11%) but nonsignificantly and remained above that of controls. Neither LV mass nor LV posterior wall thinning was correlated with reduction in BP. Patient peak systolic wall stress was initially significantly lower than that of controls. The Doppler-derived E/PWTd ratio, which was initially significantly decreased relative to that of controls, increased, becoming nonsignificantly different from that of controls. Normalization of the E/PWTd ratio suggests improved LV diastolic performance, particularly with regard to early diastolic filling. Norepinephrine (NE) decreased significantly (66%, p &gt; 0.05), suggesting that verapamil decreased overall sympathetic ad-renergic stimulation. There was no change in epinephrine or plasma renin. Thus, &gt; 1-year verapamil therapy in middle-aged hypertensive patients produces improvement in LV diastolic function and slight reduction in LV wall thickness.</description><identifier>ISSN: 0160-2446</identifier><identifier>EISSN: 1533-4023</identifier><identifier>DOI: 10.1097/00005344-199310000-00019</identifier><identifier>PMID: 7505368</identifier><identifier>CODEN: JCPCDT</identifier><language>eng</language><publisher>Philadelphia, PA: Lippincott-Raven Publishers</publisher><subject>Antihypertensive agents ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular system ; Delayed-Action Preparations ; Echocardiography - drug effects ; Electrocardiography - drug effects ; Female ; Humans ; Hypertension - drug therapy ; Hypertension - pathology ; Hypertension - physiopathology ; Male ; Medical sciences ; Middle Aged ; Myocardial Contraction - drug effects ; Myocardium - pathology ; Pharmacology. Drug treatments ; Prospective Studies ; Ventricular Function, Left - drug effects ; Verapamil - administration &amp; dosage ; Verapamil - pharmacology ; Verapamil - therapeutic use</subject><ispartof>Journal of cardiovascular pharmacology, 1993-10, Vol.22 (4), p.637-643</ispartof><rights>Lippincott-Raven Publishers.</rights><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4349-14c07dab825a6b9c360662556b220e449d8335a4f350c2dc7563c97751aa1bf53</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;NEWS=n&amp;CSC=Y&amp;PAGE=fulltext&amp;D=ovft&amp;AN=00005344-199310000-00019$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4595,27901,27902,65206</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=4914362$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/7505368$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Howley, John W</creatorcontrib><creatorcontrib>Formolo, John M</creatorcontrib><creatorcontrib>Penney, David G</creatorcontrib><title>Structural and Functional Myocardial Responses to Chronic Treatment with the Ca2+ Blocker Verapamil (Calan-SR) in Hypertensive Patients</title><title>Journal of cardiovascular pharmacology</title><addtitle>J Cardiovasc Pharmacol</addtitle><description>SUMMARYWe wished to determine whether prolonged therapy with the Ca channel blocker verapamil has beneficial structural and functional cardiac effects. Nine hypertensive outpatients [systolic blood pressure (SBP) 164 ± 4 and diastolic BP (DBF) 103 ± 4 mm Hgmen and women, blacks and whites, mean age 48.6 years] received 240–480 mg slow-release verapamil (Calan-SR) a day. BP, left ventricle (LV) wall thickness and mass, and mitral flow characteristics on echocardiography, and plasma catechols and renin were determined at 0, 5, 10, and 15 months. Patients were compared with 10 normotensive controls, of similar group composition (SBP 130 ± 3 and DBP 82 ± 1 mm Hg; age 47.2 years). In the hypertensive patients, SBP and DBP decreased significantly (p &lt; 0.05), by 14 and 12 mm Hg, respectively, but remained well above that of controls and &gt; 140/90 mm Hg. Diastolic LV septal thickness decreased from 15.3 ± 0.6 to 14.5 ± 1.1 mm (not significant), while diastolic LV posterior wall thickness (PWTd) decreased significantly (p &lt; 0.05) from 15.7 ± 0.6 to 14.1 ± 0.7 mm after 8 months, but not to the value of the controls. LV diastolic and systolic and left atrial dimensions remained constant. Normalized LV mass, initially 60% greater than the controls, decreased slightly (11%) but nonsignificantly and remained above that of controls. Neither LV mass nor LV posterior wall thinning was correlated with reduction in BP. Patient peak systolic wall stress was initially significantly lower than that of controls. The Doppler-derived E/PWTd ratio, which was initially significantly decreased relative to that of controls, increased, becoming nonsignificantly different from that of controls. Normalization of the E/PWTd ratio suggests improved LV diastolic performance, particularly with regard to early diastolic filling. Norepinephrine (NE) decreased significantly (66%, p &gt; 0.05), suggesting that verapamil decreased overall sympathetic ad-renergic stimulation. There was no change in epinephrine or plasma renin. Thus, &gt; 1-year verapamil therapy in middle-aged hypertensive patients produces improvement in LV diastolic function and slight reduction in LV wall thickness.</description><subject>Antihypertensive agents</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular system</subject><subject>Delayed-Action Preparations</subject><subject>Echocardiography - drug effects</subject><subject>Electrocardiography - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - pathology</subject><subject>Hypertension - physiopathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Contraction - drug effects</subject><subject>Myocardium - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prospective Studies</subject><subject>Ventricular Function, Left - drug effects</subject><subject>Verapamil - administration &amp; dosage</subject><subject>Verapamil - pharmacology</subject><subject>Verapamil - therapeutic use</subject><issn>0160-2446</issn><issn>1533-4023</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kt9uFCEUxonR1LX6CCZcGGNjRmH4MzuXOmmtSY2mrd6SMwyTxTIwBcbNPoGvLXXXvZPkBE7O7zuc8IEQpuQdJW3znpQlGOcVbVtGH7KqBG0foRUVjFWc1OwxWhEqSVVzLp-iZyn9LAQXjTxBJ40ocrleod83OS46LxEcBj_gi8XrbIMv6Zdd0BAHW47XJs3BJ5NwDrjbxOCtxrfRQJ6Mz3hr8wbnjcEd1G_xRxf0nYn4h4kww2QdftOBA1_dXJ9h6_HlbjYxG5_sL4O_QbalRXqOnozgknlx2E_R94vz2-6yuvr66XP34arSnPG2olyTZoB-XQuQfauZJFLWQsi-ronhvB3WjAngIxNE14NuhGS6bRpBAWg_CnaKXu_7zjHcLyZlNdmkjSvzmbAk1UjKuBRtAdd7UMeQUjSjmqOdIO4UJerBA_XPA3X0QP31oEhfHu5Y-skMR-Hh0Uv91aEOSYMbI3ht0xHjLeVM1gXje2wbXDYx3blla6LaGHB5o_73A9gfV7ad6Q</recordid><startdate>199310</startdate><enddate>199310</enddate><creator>Howley, John W</creator><creator>Formolo, John M</creator><creator>Penney, David G</creator><general>Lippincott-Raven Publishers</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199310</creationdate><title>Structural and Functional Myocardial Responses to Chronic Treatment with the Ca2+ Blocker Verapamil (Calan-SR) in Hypertensive Patients</title><author>Howley, John W ; Formolo, John M ; Penney, David G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4349-14c07dab825a6b9c360662556b220e449d8335a4f350c2dc7563c97751aa1bf53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Antihypertensive agents</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular system</topic><topic>Delayed-Action Preparations</topic><topic>Echocardiography - drug effects</topic><topic>Electrocardiography - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - pathology</topic><topic>Hypertension - physiopathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Contraction - drug effects</topic><topic>Myocardium - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prospective Studies</topic><topic>Ventricular Function, Left - drug effects</topic><topic>Verapamil - administration &amp; dosage</topic><topic>Verapamil - pharmacology</topic><topic>Verapamil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Howley, John W</creatorcontrib><creatorcontrib>Formolo, John M</creatorcontrib><creatorcontrib>Penney, David G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cardiovascular pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Howley, John W</au><au>Formolo, John M</au><au>Penney, David G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Structural and Functional Myocardial Responses to Chronic Treatment with the Ca2+ Blocker Verapamil (Calan-SR) in Hypertensive Patients</atitle><jtitle>Journal of cardiovascular pharmacology</jtitle><addtitle>J Cardiovasc Pharmacol</addtitle><date>1993-10</date><risdate>1993</risdate><volume>22</volume><issue>4</issue><spage>637</spage><epage>643</epage><pages>637-643</pages><issn>0160-2446</issn><eissn>1533-4023</eissn><coden>JCPCDT</coden><abstract>SUMMARYWe wished to determine whether prolonged therapy with the Ca channel blocker verapamil has beneficial structural and functional cardiac effects. Nine hypertensive outpatients [systolic blood pressure (SBP) 164 ± 4 and diastolic BP (DBF) 103 ± 4 mm Hgmen and women, blacks and whites, mean age 48.6 years] received 240–480 mg slow-release verapamil (Calan-SR) a day. BP, left ventricle (LV) wall thickness and mass, and mitral flow characteristics on echocardiography, and plasma catechols and renin were determined at 0, 5, 10, and 15 months. Patients were compared with 10 normotensive controls, of similar group composition (SBP 130 ± 3 and DBP 82 ± 1 mm Hg; age 47.2 years). In the hypertensive patients, SBP and DBP decreased significantly (p &lt; 0.05), by 14 and 12 mm Hg, respectively, but remained well above that of controls and &gt; 140/90 mm Hg. Diastolic LV septal thickness decreased from 15.3 ± 0.6 to 14.5 ± 1.1 mm (not significant), while diastolic LV posterior wall thickness (PWTd) decreased significantly (p &lt; 0.05) from 15.7 ± 0.6 to 14.1 ± 0.7 mm after 8 months, but not to the value of the controls. LV diastolic and systolic and left atrial dimensions remained constant. Normalized LV mass, initially 60% greater than the controls, decreased slightly (11%) but nonsignificantly and remained above that of controls. Neither LV mass nor LV posterior wall thinning was correlated with reduction in BP. Patient peak systolic wall stress was initially significantly lower than that of controls. The Doppler-derived E/PWTd ratio, which was initially significantly decreased relative to that of controls, increased, becoming nonsignificantly different from that of controls. Normalization of the E/PWTd ratio suggests improved LV diastolic performance, particularly with regard to early diastolic filling. Norepinephrine (NE) decreased significantly (66%, p &gt; 0.05), suggesting that verapamil decreased overall sympathetic ad-renergic stimulation. There was no change in epinephrine or plasma renin. Thus, &gt; 1-year verapamil therapy in middle-aged hypertensive patients produces improvement in LV diastolic function and slight reduction in LV wall thickness.</abstract><cop>Philadelphia, PA</cop><cop>Hagerstown, MD</cop><pub>Lippincott-Raven Publishers</pub><pmid>7505368</pmid><doi>10.1097/00005344-199310000-00019</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0160-2446
ispartof Journal of cardiovascular pharmacology, 1993-10, Vol.22 (4), p.637-643
issn 0160-2446
1533-4023
language eng
recordid cdi_proquest_miscellaneous_76134659
source MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete
subjects Antihypertensive agents
Biological and medical sciences
Blood Pressure - drug effects
Cardiovascular system
Delayed-Action Preparations
Echocardiography - drug effects
Electrocardiography - drug effects
Female
Humans
Hypertension - drug therapy
Hypertension - pathology
Hypertension - physiopathology
Male
Medical sciences
Middle Aged
Myocardial Contraction - drug effects
Myocardium - pathology
Pharmacology. Drug treatments
Prospective Studies
Ventricular Function, Left - drug effects
Verapamil - administration & dosage
Verapamil - pharmacology
Verapamil - therapeutic use
title Structural and Functional Myocardial Responses to Chronic Treatment with the Ca2+ Blocker Verapamil (Calan-SR) in Hypertensive Patients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T03%3A40%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Structural%20and%20Functional%20Myocardial%20Responses%20to%20Chronic%20Treatment%20with%20the%20Ca2+%20Blocker%20Verapamil%20(Calan-SR)%20in%20Hypertensive%20Patients&rft.jtitle=Journal%20of%20cardiovascular%20pharmacology&rft.au=Howley,%20John%20W&rft.date=1993-10&rft.volume=22&rft.issue=4&rft.spage=637&rft.epage=643&rft.pages=637-643&rft.issn=0160-2446&rft.eissn=1533-4023&rft.coden=JCPCDT&rft_id=info:doi/10.1097/00005344-199310000-00019&rft_dat=%3Cproquest_cross%3E76134659%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=76134659&rft_id=info:pmid/7505368&rfr_iscdi=true